PureTech's LYT-200 Shows Promising Results in Phase 1b Trial for High-Risk Blood Cancers — PureTech Health plc

Event summary

PureTech's LYT-200 demonstrated a 45.5% overall response rate in relapsed/refractory high-risk myelodysplastic syndrome (HR-MDS) and a 42.3% overall response rate in relapsed/refractory acute myeloid leukemia (AML) in a Phase 1b trial.
The trial, conducted across nine U.S. sites, included 101 patients and showed no dose-limiting toxicities or LYT-200-related serious adverse events.
PureTech's Founded Entity, Gallop Oncology, has selected a recommended Phase 2 dose and plans to engage with the FDA to discuss the design of a subsequent trial that could potentially support registration of LYT-200 in R/R HR-MDS.
LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, has been granted Fast Track and Orphan Drug designations by the FDA for the treatment of AML.

The big picture

PureTech's positive Phase 1b data for LYT-200 comes at a time when the AML and HR-MDS markets are ripe for innovation, with limited treatment options for relapsed/refractory patients. The company's strategic focus on addressing high-unmet needs in hematological malignancies aligns with broader industry trends towards precision oncology and combination therapies. The potential for LYT-200 to offer a mutation-agnostic approach could broaden its applicability across patient populations, making it a compelling asset in Gallop Oncology's pipeline.

What we're watching

Regulatory Pathway: Whether the FDA will support a registration-enabling trial design for LYT-200 in R/R HR-MDS, given the significant unmet need in this indication.
Clinical Development: The pace at which Gallop Oncology can advance LYT-200 into Phase 2 trials and potentially expand its development into other hematological malignancies.
Commercial Potential: How LYT-200's differentiated mechanism of action and favorable safety profile will position it against existing therapies in the AML and HR-MDS markets.